insight
✂️ 성형 🏥 중증 🌐 전체
← 뒤로

Neoadjuvant therapy with cadonilimab in a patient with MSI-H/dMMR colorectal cancer: a case report.

Frontiers in oncology 2025 Vol.15() p. 1693932

Zhou J, Chen W, Wang J, Chen Z, Guo G, Yang T, Shen T

PMC 전문 ↗ 원문 ↗ DOI ↗ BibTeX ↓ RIS ↓
📝 환자 설명용 한 줄

Neoadjuvant immunotherapy for mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) colorectal cancer continues to accumulate compelling clinical evidence.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Zhou J, Chen W, et al. (2025). Neoadjuvant therapy with cadonilimab in a patient with MSI-H/dMMR colorectal cancer: a case report.. Frontiers in oncology, 15, 1693932. https://doi.org/10.3389/fonc.2025.1693932
MLA Zhou J, et al.. "Neoadjuvant therapy with cadonilimab in a patient with MSI-H/dMMR colorectal cancer: a case report.." Frontiers in oncology, vol. 15, 2025, pp. 1693932.
PMID 41561746
DOI 10.3389/fonc.2025.1693932

Abstract

Neoadjuvant immunotherapy for mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) colorectal cancer continues to accumulate compelling clinical evidence. This report presents the case of a 37-year-old female who presented with moderate anemia (hemoglobin: 69 g/L) and was subsequently diagnosed with dMMR/MSI-H descending colon cancer. Following nine cycles of cadonilimab, a novel PD-1/CTLA-4 bispecific antibody, the patient achieved significant tumor regression and subsequent pathological complete response (pCR) after surgery, with a favorable safety profile observed throughout the treatment course. This case provides valuable clinical evidence supporting the efficacy and safety of cadonilimab in the neoadjuvant setting for dMMR/MSI-H colorectal cancer.

같은 제1저자의 인용 많은 논문 (5)